Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 1: 83-92, 1955;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, R. K.
Right arrow Articles by Kauffman, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, R. K.
Right arrow Articles by Kauffman, D. L.

Clinical Chemistry, Vol 1, 83-92, Copyright © 1955 by the American Association for Clinical Chemistry

Serum Lipoproteins

Chemical and Enzymatic Studies

Ray K. Brown 1, Louis S. DeLalla 1, and Dorothy L. Kauffman 1

1 Division of Laboratories and Research, New York State Department of Health, Albany, N. Y.

The larger lipoproteins of Sf greater than 10 also contain triglycerides. The action of lipases on these lipoproteins, either heparin-induced clearing factor, pancreatic lipase, or gastric lipase, yields fatty acids, glycerol, and smaller lipoproteins. Crude clearing factor attacks monoglycerides and triglycerides and is inactiveagainst several esters which plasma esterases attack. Albumin, plasma esterases, and probably other components are needed for optimal clearing factor activity. Low concentrations of diisopropyl fluorophosphate (DFP), a substance inhibiting most hydrolytic enzymes, inactivate crude clearing factor. Stoicheometric calculations made from this experiment indicate further the enzymatic nature of clearing factor. Evidence that clearing factor is different from other lipases and from esterases found in plasma is presented.

Studies with purified lipoproteins are needed to determine what alterations, if any, occur in smaller lipoproteins. The separation and purification of lipoproteins by chemical and ultracentrifugal means are described. Whole human plasma separated by Cohn's methods 6 and 9 serves as starting material for the preparation of alpha1 alpha2 beta and Sf 10 and greater lipoproteins.

Studies of lipoproteins may give clues to the varied diseases associated with deranged lipid metabolism, such as xanthomatosis and atherosclerosis.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. Rej
Clinical Chemistry through Clinical Chemistry: A Journal Timeline
Clin. Chem., December 1, 2004; 50(12): 2415 - 2458.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1955 by the American Association for Clinical Chemistry.